| Literature DB >> 31929514 |
Chun-Pin Chang1, Carlo La Vecchia2, Diego Serraino3, Andrew F Olshan4, Jose P Zevallos5, Hal Morgenstern6, Fabio Levi7, Werner Garavello8, Karl Kelsey9, Michael McClean10, Chu Chen11, Stephen M Schwartz11, Stimson Schantz12, Guo-Pei Yu13, Paolo Boffetta14,15, Mia Hashibe1, Yuan-Chin Amy Lee1, Maria Parpinel16, Livia S A Augustin17,18, Federica Turati2, Zuo-Feng Zhang19, Valeria Edefonti20.
Abstract
High dietary glycaemic index (GI) and glycaemic load (GL) may increase cancer risk. However, limited information was available on GI and/or GL and head and neck cancer (HNC) risk. We conducted a pooled analysis on 8 case-control studies (4081 HNC cases; 7407 controls) from the International Head and Neck Cancer Epidemiology (INHANCE) consortium. We estimated the odds ratios (ORs) and 95% confidence intervals (CIs) of HNC, and its subsites, from fixed- or mixed-effects logistic models including centre-specific quartiles of GI or GL. GI, but not GL, had a weak positive association with HNC (ORQ4 vs. Q1 = 1.16; 95% CI = 1.02-1.31). In subsites, we found a positive association between GI and laryngeal cancer (ORQ4 vs. Q1 = 1.60; 95% CI = 1.30-1.96) and an inverse association between GL and oropharyngeal cancer (ORQ4 vs. Q1 = 0.78; 95% CI = 0.63-0.97). This pooled analysis indicates a modest positive association between GI and HNC, mainly driven by laryngeal cancer.Entities:
Mesh:
Year: 2020 PMID: 31929514 PMCID: PMC7078183 DOI: 10.1038/s41416-019-0702-4
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Odds ratios (ORs)a and 95% confidence intervals (CIs) of glycaemic index and glycaemic load on cancers of head and neck, oral cavity, oropharynx, hypopharynx and larynx.
| Head and neck cancer (No. cases = 3967, No. controls = 7250b) | Oral cavity cancer (No. cases = 780, No. controls = 7250b) | Oropharyngeal cancer (No. cases = 1151, No. controls = 7250b) | Hypopharyngeal cancer (No. cases = 328, No. controls = 6866b) | Laryngeal cancer (No. cases = 11,299, No. controls = 6443b) | |
|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Glycaemic index | |||||
| I Quartile | Reference | Reference | Reference | Reference | Reference |
| II Quartile | 1.04 (0.91, 1.18) | 0.92 (0.70, 1.20) | 0.93 (0.77, 1.13) | 0.87 (0.61, 1.23) | 1.33 (1.08, 1.65) |
| III Quartile | 1.02 (0.90, 1.17) | 1.08 (0.66, 1.75) | 0.90 (0.74, 1.09) | 0.95 (0.68, 1.35) | 1.28 (1.04, 1.59) |
| IV Quartile | 1.16 (1.02, 1.31) | 1.21 (0.81, 1.81) | 0.93 (0.76, 1.12) | 0.84 (0.59, 1.20) | 1.60 (1.30, 1.96) |
| Pfor linear trend | 0.037 | 0.63 | 0.40 | 0.46 | <0.001 |
| Pheterogeneityc,d | 0.35 | 0.03 | 0.41 | 0.22 | 0.66 |
| Glycaemic load | |||||
| I Quartile | Reference | Reference | Reference | Reference | Reference |
| II Quartile | 0.94 (0.82, 1.07) | 0.88 (0.70, 1.12) | 0.91 (0.75, 1.11) | 0.78 (0.54, 1.13) | 0.95 (0.76, 1.18) |
| III Quartile | 0.89 (0.78, 1.02) | 0.86 (0.68, 1.10) | 0.75 (0.61, 0.92) | 0.74 (0.51, 1.09) | 1.03 (0.83, 1.28) |
| IV Quartile | 0.91 (0.79, 1.05) | 0.89 (0.69, 1.15) | 0.78 (0.63, 0.97) | 0.84 (0.57, 1.22) | 1.03 (0.82, 1.28) |
| Pfor linear trend | 0.15 | 0.37 | 0.009 | 0.41 | 0.63 |
| Pheterogeneityc,d | 0.52 | 0.30 | 0.97 | 0.24 | 0.68 |
International Head and Neck Cancer Epidemiology (INHANCE) consortium
aModels adjusted for age, sex, race/ethnicity, study center, education level, center-specific control-based quartiles of energy intake (without alcohol for glycaemic index; without alcohol and carbohydrate for glycaemic load), cigarette smoking intensity (number of cigarettes per day), cigarette smoking duration, cigar smoking status, pipe smoking status, alcohol drinking intensity (number of drinks per day) and the product (interaction) term for cigarette smoking intensity and alcohol drinking intensity
bThe number of controls differed across subsites because a few studies considered cancers of the oral cavity, oropharynx and hypopharynx only; therefore, they contributed to the analysis with fewer controls than those studies with all cancer subsites included (see Supplementary Table 4)
cP-value for heterogeneity between study centers
dBased on the likelihood ratio test of heterogeneity between study centers, we reported the fixed-effects estimates when Pheterogeneity > 0.1 and the mixed-effects estimates when Pstudies < 0.1